TRENDING : #Q1 Earnings 2018

Biocon gets crucial recommendation for biosimilar Trastuzumab in US

The approval of the Oncologic Drugs Advsiory Committee for Biocon's breast cancer drug is a shot in the arm for the company and improves its chances of getting a final nod for the drug from the regulator

Published: Jul 14, 2017

Over a decade in financial journalism, I have specialized in covering news that matters to India Inc. and its stakeholders, including developments at India's largest corporations and and MNCs. The subject of my writing has been analysis of strategy, financial performance, M&A and fundraising activity, consumption behaviour and emerging trends in management and leadership. Industry verticals that I have written on include oil & gas, power, infra, metals & mining, auto, telecom, FMCG & retail, and start-ups. I also play the role of an editorial lead for proprietary events like the Forbes India Leadership Award and the Forbes India CEO Dialogues. An alumnus of Asian College of Journalism, Chennai and Jadavpur University, Kolkata, I have worked for publications such as Mint, The Financial Express and The Indian Express before this.

mg_97943_biocon_bg_280x210.jpg
Biocon chairman and managing director Kiran Mazumdar-Shaw
Image:Bmaximage

 

India’s largest biopharmaceutical company Biocon inched closer to its goal of launching biosimilars in the US, with the US Food and Drug Administration’s (USFDA) Oncologic Drugs Advisory Committee (ODAC) voting unanimously in favour of a potential blockbuster drug being developed by the Bengaluru-based company and its partner Mylan.

The company, led by India’s richest self-made woman (as per the Forbes India Rich List 2016) Kiran Mazumdar-Shaw, announced on Friday that the ODAC recommended approval of Biocon and Mylan’s proposed biosimilar Trastuzumab, which is used for the treatment of breast cancer.

“Data presented to ODAC included results from analytical, nonclinical and clinical studies which demonstrated that our proposed biosimilar Trastuzumab is highly similar to Herceptin (the original drug), in line with the FDA assessment provided in the pre-meeting briefing documents,” Biocon said in a statement to the bourses.

The Street, which for long had accorded a lower valuation to Biocon than some other small-molecule generic drugmakers due the relative immediacy of the latter’s returns on investment, has been bullish on Biocon since its biosimilars program started gathering steam. On Friday as well, Biocon’s shares outperformed the market. At 2:36 pm, Biocon’s shares were trading at Rs 399.70 apiece, up 9.01 percent, on the BSE. The benchmark S&P BSE Sensex was down 0.13 percent at the same time at 31,990.18 points.

To be sure, this ODAC’s recommendation is only one – though important – step towards Trastuzumab’s eventual commercialization in the US, for which it will need a final seal of approval from the USFDA. The drug is also under review (for approval) by regulatory authorities in Australia, Canada, Europe and several emerging markets.

Apart from Trastuzumab, Biocon is also working towards filing for approval pertaining to three other biosimilar drugs across the US and Europe. These drugs have either completed Phase-III trials or are in advanced stages of doing so.

Biocon has a robust pipeline of 10 biosimilar drugs (including different types of insulin) under development with an addressable market size of $60 billion. In order to diversify the risk associated with the development of these products, Biocon has partnered with US generic drug-maker Mylan. The strategic collaboration leverages Biocon’s development and manufacturing capabilities and Mylan’s regulatory and commercial expertise.

Arun Chandavarkar, Biocon’s chief executive officer and joint managing director said in the company’s statement issued Friday that the ODAC’s endorsement brought the company a step closer to “addressing the critical needs of cancer patients in the US.”

“We now look forward to engaging with the FDA to seek final approval in order to expand access to a high-quality, affordable option for treating HER2-positive breast cancers,” Chandavarkar said.

Show More
Ten interesting things that we read this week
HDFC Life-Max Life merger decision likely on July 17
You might also want to read
next
prev
related stories